目的 观察单个核细胞趋化蛋白-1MCP-1及其受体CCR2在多发性骨髓瘤(MM)患者骨髓瘤细胞和骨髓基质细胞中的表达.方法 经国内统一标准确诊为MM的患者15例,男7例,女8例,年龄38～67岁,平均年龄53.7岁.按照Durie-Salmon分期系统分期,Ⅰ期2例、Ⅱ期5例、Ⅲ期8例.其他血液病患者10例为对照组.取样本进行骨髓瘤细胞与骨髓基质细胞的分离培养,在含13％胎牛血清的RPMI 1640培养液中培养,每2d更换1次培养液,实验用细胞均处于对数生长期.采用流式细胞术检测骨髓瘤患者骨髓瘤细胞,骨髓基质细胞中MCP-1、CCR2水平.结果 14例MM患者骨髓均表达MCP-1、CCR2,而对照组8例骨髓中趋化因子MCP-1、CCR2基本无表达.对照组和MM患者基质细胞上MCP-1、CCR2均阳性的表达率分别为4.27％和68.71％,两组比较差异具有统计学意义(P＜0.05).瘤细胞上MCP-1、CCR2均阳性的表达率分别为3.25％和32.76％,两组比较差异具有统计学意义(P＜0.05).处于疾病活动期的基质细胞和瘤细胞上MCP-1、CCR2均阳性的表达率分别为68.71％和32.76％,而处于疾病非活动期的的基质细胞和瘤细胞上MCP-1、CCR2均阳性的表达率分别为70.12％和53.39％,两组比较差异无统计学意义(P＞0.05).结论 大部分MM患者骨髓均表达MCP-1、CCR2.MCP-1及CCR2是MM细胞表面表达的主要趋化因子,对MM的疾病进展起着一个比较重要的作用.%Objective To observe the expression of chemokine (MCP-1) and chemokine receptor (CCR2) in bone marrow cells,bone marrow stromal cells of multiple myeloma (MM) patients.Methods 15 cases were diagnosed by domestic uniform standard for MM patients,7 cases of male,8 cases of female,age range from 38 to 67 years,mean age 53.7 years old.According to the Durie-Salmon staging system,patients were divided into Ⅰ (2 cases),Ⅱ (5 cases) and Ⅲ period(8 cases).Control group were from 10 cases of non-malignant blood disease patients.MCP-1,CCR2 expression were measured by flow cytometry.Results Almost 14 cases of bone marrow cells expressed MCP-1and CCR2 in MM patients,while in the control group,bone marrow cells almost did not express MCP-1and CCR2.Stromal cells had similar MCP-1and CCR2 expression profile (68.17 ％ vs 4.27 ％. P＜0.05).Tumor cells of MCP-1/CCR2 expression rates were 3.25 ％ and 32.76 ％. Compared MCP-1/ CCR2 expression of stromal cells and tumor cells with different stages of disease, the activated stage and the stable stage had similar level (68.71％ and 32.76 ％ vs 70.12 ％ and 53.39 ％. P＞0.05). Conclusion Most patients with MM bone marrow were expressed MCP-1and CCR2.MCP-1and CCR2 are the major MM cell surface expression of chemokine/receptor, which play important roles in the progress of.
展开▼
